Last reviewed · How we verify

NCT05248594

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Completed Last updated 8 September 2025
What this trial tests

trial testing HEMLIBRA in Hemophilia A in 71 participants. Completed in 18 July 2025.

Timeline
1 August 2024
Primary endpoint
18 July 2025
18 July 2025

Quick facts

Lead sponsorMontefiore Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment71
Start date1 August 2024
Primary completion18 July 2025
Estimated completion18 July 2025
Sites10 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Montefiore Medical Center

Who can join

Under 36 Months, any sex, with Hemophilia A. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII deficiency. In severe HA, defined as plasma FVIII clotting activity \< 1%, bleeding may frequently occur spontaneously, most commonly in joints, leading to painful hemophilic arthropathy and loss of joint function. Patients with moderate or mild hemophilia A, defined as FVIII clotting activity between 1-\<5% and 5-40% respectively, are less likely to have spontaneous bleeding however can have significant bleeding with trauma or surgery. Perioperative management by a hematologist who specializes in hemophilia is needed to ensure hemostasis during surgery. Hemophilia is an X-linked recessive disorder affecting 1 in 5000 to 10,000 males.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of HEMLIBRA

Trials testing the same drug.

Other recruiting trials for Hemophilia A

Currently open trials in the same condition.

Other Montefiore Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05248594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing